Hospital-Associated Infections Market May Decline Due to Patent Expiries
The global hospital-associated bacterial infections market is forecast to reach $1.4 billion by 2016, indicated a reduced growth rate due to patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2009, according to a GBI Research news release.
The global hospital-acquired bacterial infections market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs for urinary tract infections, pneumonia, surgical site infections and bloodstream infections. The major drugs that are set to lose patent protection include Zyvox (linezolid, 2013), Levaquin (levofloxacin, 2010), Invanz (ertapenem, 2013) and Tobi (tobramycin, 2014).
Read the news release about the hospital-associated infections market.
Read other coverage about medical supplies markets:
- Medical Device Market to Present Greater Opportunities, Greater Challenges to - Companies
- 6 Predictions on Device Market Growth in the Next Five Years
- FDA Announces 25 Actions to Improve Medical Device Approval Process
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- ASC Industry Leader to Know: Dr. Gregory Lauro of Laurel Surgical Center
- Ambulatory Alliances Releases Free Webinar on Valuing Ambulatory Surgery Centers
- Louisville Endoscopy Center Earns Three-Year AAAHC Accreditation
- Pain Physician Joins Sarasota Pain Management
- Fentanyl Spray Deemed Safe for Cancer Pain Patients
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,504.48 Trade time:4:02PM EDT Value change:▲135.10 (1.09%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,847.21 Trade time:5:16PM EDT Value change:0.00 (0.00%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,315.99 Trade time:4:32PM EDT Value change:0.00 (0.00%)
Channels
